"The US Food and Drug Administration (FDA) has approved lenvatinib (Lenvima, Eisai), in combination with everolimus, for the treatment of patients with advanced renal cell carcinoma who were previously treated with an anti-angiogenic ther"...
IMPORTANT: HOW TO USE THIS INFORMATION: This is a summary and does NOT have all possible information about this product. This information does not assure that this product is safe, effective, or appropriate for you. This information is not individual medical advice and does not substitute for the advice of your health care professional. Always ask your health care professional for complete information about this product and your specific health needs.
CARMUSTINE - INJECTION
COMMON BRAND NAME(S): BiCNU
WARNING: This medication may cause very serious blood disorders (decreased bone marrow function leading to low number of blood cells such as red cells, white cells, and platelets). These effects can cause anemia, decrease your body's ability to fight an infection, or cause your body to bruise or bleed more easily. If these effects occur, it is usually 4 to 6 weeks after the medication is given. Your doctor will monitor your blood counts for at least 6 weeks after your dose of the medication. Tell your doctor immediately if you develop any of the following symptoms: signs of infection (e.g., fever, persistent sore throat), easy bruising/bleeding, unusual tiredness, fast/pounding heartbeat.
This medication may also cause very serious (possibly fatal) lung problems. The lung problems can occur years after treatment. Tell your doctor immediately if you develop any of the following symptoms: shortness of breath, persistent cough, chest pain, persistent weakness/tiredness.
USES: This medication is used to treat certain types of cancer (e.g., multiple myeloma, brain tumor, Hodgkin's disease, non-Hodgkin's lymphoma). Carmustine belongs to a class of drugs known as alkylating agents. It works by slowing or stopping the growth of cancer cells.
HOW TO USE: This medication is given by injection into a vein by a health care professional. Dosage is based on your medical condition, body size, and response to treatment. This medication is usually given every 6 weeks or as directed by your doctor.
Additional BiCNU Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Get the latest treatment options.